# An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

> **NCT01889433** · PHASE3 · COMPLETED · sponsor: **Biocad** · enrollment: 170 (actual)

## Conditions studied

- Hepatitis
- Hepatitis C

## Interventions

- **DRUG:** Algeron
- **DRUG:** Pegasys

## Key facts

- **NCT ID:** NCT01889433
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-10
- **Primary completion:** 2015-12-02
- **Final completion:** 2015-12-02
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2018-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01889433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01889433, "An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01889433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*